- $11.72m
- $11.67m
- $41.71m
Brief: Biofrontera Files Prospectus Relates To Offering And Resale From Time To Time Of 9.31 Million Shares Of Common Stock Offered By Selling Stockholders
Brief: Biofrontera Notified Its Licensor For Ameluz, Biofrontera AG, Initiated Voluntary Recall Of Limited Number Of Lots Of Ameluz
Brief: Biofrontera Inc Announces FDA Filing Of Supplemental New Drug Application For Ameluz To Permit Up To Three Tubes Per Use
Brief: Biofrontera Says On Dec 29, Co Entered Confidential Settlement Agreement & Mutual Release Dated As Of Dec 27 & Effective As Of Dec 22, 2023, With Maruho
U.S. STOCKS ON THE MOVE-American Airlines, Netflix, Tesla
Brief: Biofrontera Inc - Receives FDA Approval For New Formulation Of Ameluz(R)
Brief: Biofrontera Says On Sept 13, Co Served With Complaint Filed In U.S. District Court By DUSA
Brief: Biofrontera Inc Begins Development Of A Portable Photodynamic Therapy Lamp For Use With Ameluz®-Pdt
Brief: Biofrontera Appoints Executive Chairman Hermann Luebbert As CEO
Biofrontera falls as Q1 revenue misses, CEO resigns
Brief: Biofrontera Inc - On April 26, Executed Amendment No. 1 To Stockholder Rights Agreement , Effective As Of April 26
Brief: Biofrontera Inc Enters Settlement Agreement With Biofrontera AG
Brief: Biofrontera Inc Fourth Quarter 2022 Total Revenues $10.1 Mln
Brief: Biofrontera Inc Receives Delisting Notice From Nasdaq
Brief: Biofrontera Inc Says Revenues For The Q4 2022 Are Anticipated To Be In The Range Of About $10.2 Mln To $10.4 Mln
Brief: Biofrontera To Launch Phase 3 Clinical Study Evaluating Ameluz®-Pdt For The Treatment Of Actinic Keratosis On The Extremities, Neck And Trunk
Brief: Biofrontera Inc. Reports Third Quarter 2022 Financial Results, Provides A Business Update
Biofrontera Inc reports results for the quarter ended in September - Earnings Summary
Brief: Biofrontera Inc Fully Exercises Recently Acquired Options To Purchase Shares Of Biofrontera AG